

AMS WEBINAR

This AMS webinar is designed as a wrap-up of expert opinion, up-to-date management options, and best-practice recommendations for menopause management, based on the diversity of the expert presentations at the 19th World IMS Congress in Melbourne a few months ago, and the recent IMS White Paper.

The 19th World Congress afforded Australian healthcare providers the opportunity to explore best-practice menopause care recommendations, and our hive mind has been buzzing with a range of opinions related to risk vs benefit of MHT, new and emerging non-MHT treatment options, alongside the most effective ways of conveying evidence-based information to women in our ongoing efforts to counter information overload and misinformation. In addition, we have had the exciting announcements of new dosage options now available for existing MHT formulations, as well as new additions to the PBS list for MHT, offering a wider choice for women.

The AMS webinar is designed as a wrap-up of expert opinion, the menopause toolkit, and best-practice recommendations for menopause management, based on the diversity of the expert presentations at the 19th World IMS Congress a few months ago, and the IMS White Paper.

RACGP activity no: 1144524

Event Learning outcomes

1. Describe the different non-hormonal treatment options to manage symptoms of menopause.
2. Assess the risks and benefits of initiating, continuing or ceasing/not initiating MHT and non-MHT.
3. Describe the most effective ways of conveying evidence-based information on menopause to counter information overload and misinformation.
4. Assess the new and emerging non-MHT treatment options on the PBS.

Attending the webinar RACGP hours:

Educational Activities: 1.5 HOURS

After the webinar RACGP hours:

Measuring Outcomes: 5 HOURS

Reviewing Performance: 2 HOURS

After the webinar, participants will be invited to complete a mini audit over a three-month window.

RACGP hours for the mini audit:

The audit will involve reviewing the consultations of 10-20 patients from the past 12 months. Participants will assess whether discussions on the benefits and risks of initiating, continuing, ceasing, or not starting Menopausal Hormone Therapy (MHT) and non-MHT options have taken place, and whether these discussions have been documented. Patients who have not had these conversations will be flagged for further review.

Participants will then be encouraged to follow up on these findings, integrating best-practice approaches from the IMS World Congress ([Figure 1. Implementing guidance from the 19th World Congress on Menopause into routine clinical practice](#)).

Finally, participants will reflect on their practice to ensure they can apply these best practices in future consultations.

BOOKINGS: www.trybooking.com/CZNWL

Tuesday 18 March 2025, 6:00PM AEDT

Free for members

\$49 including gst (plus booking fee) for non-members



FEATURING:
Professor Rodney Baber
and Dr Terri Foran
Moderated by Dr Lina Safro



**AUSTRALASIAN
MENOPAUSE
SOCIETY**
EMPOWERING MENOPAUSAL WOMEN